Merck To Work With AmoyDx On Colorectal Cancer Liquid Biopsy Assay

Germany-based Merck will work to develop the test based on AmoyDx's real-time polymerase chain reaction technology, with goals to launch in China in 2017.

Merck KGAA is teaming up with Xiamen, China-based Amoy Diagnostics Co. Ltd. to develop and commercialize a new liquid-biopsy RAS biomarker for metastatic colorectal cancer based on Amoy’s ADx-SuperARMS real-time polymerase chain reaction technology.

The companies expect to launch the new assay in China in 2017, and then expand it to Argentina, India, Mexico,...

More from In Vitro Diagnostics

More from Diagnostics